ALX Oncology Holdings Future Growth
Future criteria checks 0/6
ALX Oncology Holdings wird ein jährliches Wachstum der Erträge und Einnahmen um 11.5% bzw. 71.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 24% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -831.9% betragen.
Key information
11.5%
Earnings growth rate
24.0%
EPS growth rate
Biotechs earnings growth | 20.9% |
Revenue growth rate | 71.2% |
Future return on equity | -831.9% |
Analyst coverage | Low |
Last updated | 13 Mar 2024 |
Recent future growth updates
Recent updates
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
Feb 15ALX Oncology Stock: Attractive After Recent Data And Slump In Price
Nov 30ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
Sep 08Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer
May 10We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like
Feb 01ALX Oncology: All Their Eggs In The Proverbial Basket
Jan 07ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 11ALX Oncology prices upsized stock offering at $76
Dec 10ALX Oncology announces proposed public offering
Dec 07ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow
Nov 20ALX Oncology reports Q3 results
Nov 12Dosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study
Oct 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 11 | -191 | -211 | -215 | 5 |
12/31/2025 | N/A | -171 | -132 | -190 | 4 |
12/31/2024 | N/A | -173 | -119 | -190 | 5 |
12/31/2023 | N/A | -161 | -132 | -130 | N/A |
9/30/2023 | N/A | -146 | -113 | -111 | N/A |
6/30/2023 | N/A | -130 | -114 | -111 | N/A |
3/31/2023 | N/A | -129 | -98 | -96 | N/A |
12/31/2022 | N/A | -123 | -91 | -89 | N/A |
9/30/2022 | N/A | -121 | -92 | -86 | N/A |
6/30/2022 | N/A | -110 | -86 | -80 | N/A |
3/31/2022 | N/A | -94 | -89 | -84 | N/A |
12/31/2021 | N/A | -83 | -73 | -68 | N/A |
9/30/2021 | N/A | -74 | -65 | -64 | N/A |
6/30/2021 | N/A | -60 | -49 | -49 | N/A |
3/31/2021 | 1 | -58 | -34 | -34 | N/A |
12/31/2020 | 1 | -51 | -38 | -38 | N/A |
9/30/2020 | 2 | -41 | -28 | -28 | N/A |
6/30/2020 | 4 | -34 | -21 | -21 | N/A |
3/31/2020 | 4 | -26 | -20 | -19 | N/A |
12/31/2019 | 5 | -23 | -15 | -14 | N/A |
12/31/2018 | 2 | -17 | -14 | -13 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: ALXO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ALXO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ALXO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ALXO wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: ALXO wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: ALXO wird voraussichtlich in 3 Jahren unrentabel sein.